HUE036664T2 - Készítmény anti-alfa4béta7 antitesthez - Google Patents
Készítmény anti-alfa4béta7 antitesthezInfo
- Publication number
- HUE036664T2 HUE036664T2 HUE12722973A HUE12722973A HUE036664T2 HU E036664 T2 HUE036664 T2 HU E036664T2 HU E12722973 A HUE12722973 A HU E12722973A HU E12722973 A HUE12722973 A HU E12722973A HU E036664 T2 HUE036664 T2 HU E036664T2
- Authority
- HU
- Hungary
- Prior art keywords
- antibody
- formulation
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161481522P | 2011-05-02 | 2011-05-02 | |
US201161544054P | 2011-10-06 | 2011-10-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE036664T2 true HUE036664T2 (hu) | 2018-07-30 |
Family
ID=46147702
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE12722973A HUE036664T2 (hu) | 2011-05-02 | 2012-05-02 | Készítmény anti-alfa4béta7 antitesthez |
Country Status (37)
Country | Link |
---|---|
US (6) | US10040855B2 (hu) |
EP (5) | EP4403579A3 (hu) |
JP (5) | JP6190359B2 (hu) |
KR (7) | KR102014512B1 (hu) |
CN (4) | CN103533959B (hu) |
AR (1) | AR086238A1 (hu) |
AU (5) | AU2012250872B2 (hu) |
CA (2) | CA3051418C (hu) |
CL (3) | CL2013003145A1 (hu) |
CO (1) | CO6801648A2 (hu) |
CR (1) | CR20130556A (hu) |
CY (1) | CY1119436T1 (hu) |
DK (1) | DK2704742T3 (hu) |
DO (1) | DOP2013000252A (hu) |
EA (1) | EA032625B1 (hu) |
EC (1) | ECSP22046340A (hu) |
ES (1) | ES2646717T3 (hu) |
GE (1) | GEP20186866B (hu) |
HK (1) | HK1253911A1 (hu) |
HR (1) | HRP20171457T1 (hu) |
HU (1) | HUE036664T2 (hu) |
IL (6) | IL305583A (hu) |
LT (1) | LT2704742T (hu) |
ME (1) | ME02858B (hu) |
MX (4) | MX367097B (hu) |
MY (1) | MY188820A (hu) |
PE (1) | PE20141672A1 (hu) |
PH (2) | PH12018502221A1 (hu) |
PL (1) | PL2704742T3 (hu) |
PT (1) | PT2704742T (hu) |
RS (1) | RS56429B1 (hu) |
SG (1) | SG194730A1 (hu) |
SI (1) | SI2704742T1 (hu) |
TW (5) | TWI832619B (hu) |
UY (1) | UY34054A (hu) |
WO (1) | WO2012151247A2 (hu) |
ZA (2) | ZA201308168B (hu) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE057244T2 (hu) | 2010-01-06 | 2022-04-28 | Takeda Pharmaceuticals Co | Plazma kallikreint kötõ fehérjék |
MX344294B (es) * | 2010-10-06 | 2016-12-13 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r). |
KR102107695B1 (ko) | 2011-01-06 | 2020-05-07 | 다이액스 코포레이션 | 혈장 칼리크레인 결합 단백질 |
EP3395836B1 (en) | 2011-01-28 | 2021-04-28 | Sanofi Biotechnology | Human antibodies to pcsk9 for use in methods of treating particular groups of subjects |
TWI832619B (zh) * | 2011-05-02 | 2024-02-11 | 美商千禧製藥公司 | 抗-α4β7抗體之調配物 |
UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
MX343324B (es) | 2011-07-06 | 2016-11-01 | Nestec Sa | Ensayos para detectar auto anticuerpos neutralizadores de la terapia biologica con tnf alpha. |
AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
US9764093B2 (en) * | 2012-11-30 | 2017-09-19 | Sio2 Medical Products, Inc. | Controlling the uniformity of PECVD deposition |
CA3208188A1 (en) | 2013-03-15 | 2014-09-25 | Takeda Pharmaceutical Company Limited | Anti-plasma kallikrein antibodies |
WO2015000082A1 (en) * | 2013-07-05 | 2015-01-08 | Integra Medical Inc. | Oral compositions |
BR112016011224A2 (pt) * | 2013-11-29 | 2017-09-19 | Ares Trading Sa | Formulação líquida de uma proteína de fusão que compreende tnfr e região de fc |
CN106459210A (zh) | 2014-03-27 | 2017-02-22 | 戴埃克斯有限公司 | 用于治疗糖尿病黄斑性水肿的组合物和方法 |
CA3224013A1 (en) | 2014-10-06 | 2016-04-14 | Chemocentryx, Inc. | Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies |
WO2016086147A1 (en) | 2014-11-26 | 2016-06-02 | Millennium Pharmaceuticals, Inc. | Vedolizumab for the treatment of fistulizing crohn's disease |
KR20170088995A (ko) * | 2014-12-03 | 2017-08-02 | 체에스엘 베링 아게 | 면역글로불린을 포함하는 안정성이 증가된 약제학적 제품 |
AU2015356613A1 (en) | 2014-12-05 | 2017-06-15 | Société des Produits Nestlé S.A. | Indirect homogeneous mobility shift assays for the detection of biologics in patient samples |
WO2016105572A1 (en) | 2014-12-24 | 2016-06-30 | Millennium Pharmaceuticals, Inc. | PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-α4β7 INTEGRIN ANTIBODY |
MA41636A (fr) | 2015-03-06 | 2018-01-09 | Millennium Pharm Inc | Méthode de traitement de la cholangite sclérosante primitive |
EA201792161A1 (ru) * | 2015-03-30 | 2018-04-30 | Дайэкс Корп. | Ингибиторы калликреинов плазмы и их применение для профилактики приступа наследственного ангионевротического отека |
KR20180034672A (ko) | 2015-08-18 | 2018-04-04 | 리제너론 파아마슈티컬스, 인크. | 지단백질 분리반출술을 경험하고 있는 고지혈증을 갖는 환자를 치료하기 위한 항-pcsk9 억제성 항체 |
CO2018007151A2 (es) | 2015-12-11 | 2018-09-20 | Dyax Corp | Inhibidores de calicreína plasmática y usos de los mismos para tratar ataque de angioedema hereditario |
KR20180098625A (ko) * | 2015-12-30 | 2018-09-04 | 제넨테크, 인크. | 분해가 감소된 폴리소르베이트를 갖는 제형 |
USD866757S1 (en) | 2016-03-11 | 2019-11-12 | Millennium Pharmaceuticals, Inc. | Autoinjector |
WO2017160700A1 (en) | 2016-03-14 | 2017-09-21 | Millennium Pharmaceuticals, Inc. | Methods of treating or preventing graft versus host disease |
KR102710759B1 (ko) * | 2016-03-14 | 2024-09-25 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 이식편대숙주 질환을 예방하는 방법 |
TW201735949A (zh) | 2016-03-24 | 2017-10-16 | 千禧製藥公司 | 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法 |
WO2017165778A1 (en) | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments |
EP3452070A1 (en) | 2016-05-04 | 2019-03-13 | Millennium Pharmaceuticals, Inc. | Triple combination therapy for treating inflammatory bowel disease |
MA45245A (fr) | 2016-06-12 | 2019-04-17 | Millennium Pharm Inc | Méthode de traitement de maladie intestinale inflammatoire |
JOP20170170B1 (ar) * | 2016-08-31 | 2022-09-15 | Omeros Corp | صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق |
WO2018104893A1 (en) | 2016-12-06 | 2018-06-14 | Glaxosmithkline Intellectual Property Development Limited | Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life |
PE20191436A1 (es) * | 2016-12-23 | 2019-10-14 | Serum Institute Of India Pvt Ltd | Metodos mejorados para estimular la productividad de anticuerpos en el cultivo de celulas de mamiferos y reducir la agregacion durante los procesos de formulacion post-tratamiento (downstream) y formulaciones de anticuerpos estables obtenidas a partir de los mismos |
CN108686204A (zh) * | 2017-04-07 | 2018-10-23 | 浙江海正药业股份有限公司 | 包含组氨酸缓冲体系的英夫利西单抗组合物 |
US20200179486A1 (en) | 2017-04-28 | 2020-06-11 | Millennium Pharmaceuticals, Inc. | Method of treating pediatric disorders |
CA3072913A1 (en) * | 2017-08-25 | 2019-02-28 | Omeros Corporation | Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods of treating subjects suffering from atypical hemolytic syndrome |
CN112243379A (zh) * | 2018-04-10 | 2021-01-19 | 雷迪博士实验室有限公司 | 稳定的抗体制剂 |
AU2019251453A1 (en) * | 2018-04-10 | 2020-11-26 | Dr. Reddy’S Laboratories Limited | Stable formulations of therapeutic antibody |
EP3773694A4 (en) * | 2018-04-10 | 2021-12-29 | Dr. Reddy's Laboratories Ltd. | Antibody formulation |
US20210187107A1 (en) * | 2018-08-29 | 2021-06-24 | Glaxosmithkline Intellectual Property Development Limited | Methods of preparing stable liquid therapeutic protein compositions |
CA3124701A1 (en) * | 2019-01-08 | 2020-07-16 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
JP7266108B2 (ja) | 2019-02-18 | 2023-04-27 | イーライ リリー アンド カンパニー | 治療用抗体製剤 |
BR112021024848A2 (pt) * | 2019-06-10 | 2022-01-18 | Takeda Pharmaceuticals Co | Métodos de purificação de anticorpos e composições dos mesmos |
EP4041761A4 (en) * | 2019-10-11 | 2023-10-25 | Dr. Reddy's Laboratories Limited | STABLE FORMULATION OF INTEGRIN ANTIBODIES |
WO2022026699A1 (en) * | 2020-07-31 | 2022-02-03 | Genentech, Inc. | Anti-integrin beta7 antibody formulations and devices |
WO2022101935A1 (en) * | 2020-11-12 | 2022-05-19 | Dr. Reddy’S Laboratories Limited | Stable aqueous high concentration formulation of integrin antibody |
WO2022123603A1 (en) * | 2020-12-09 | 2022-06-16 | Dr. Reddy's Laboratories Limited | Stable aqueous buffer free formulation of an integrin antibody |
WO2022253994A1 (en) * | 2021-06-04 | 2022-12-08 | Polpharma Biologics S.A. | Vedolizumab formulation |
CN113813377A (zh) * | 2021-09-07 | 2021-12-21 | 杭州远大生物制药有限公司 | 抗α4β7抗体制剂及其应用 |
EP4456917A1 (en) | 2021-12-27 | 2024-11-06 | Polpharma Biologics S.A. | Vedolizumab formulation |
WO2023230620A1 (en) * | 2022-05-27 | 2023-11-30 | Sonnet BioTherapeutics, Inc. | Il-12-albumin-binding domain fusion protein formulations and methods of use thereof |
US12134635B1 (en) | 2023-12-29 | 2024-11-05 | Sonnet BioTherapeutics, Inc. | Interleukin 18 (IL-18) variants and fusion proteins comprising same |
Family Cites Families (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US4699880A (en) | 1984-09-25 | 1987-10-13 | Immunomedics, Inc. | Method of producing monoclonal anti-idiotype antibody |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US5538724A (en) | 1987-08-11 | 1996-07-23 | The Board Of Trustees For The Leland Stanford Junior Univ. | Method of control leukocyte extravasation |
US5403919A (en) | 1987-08-11 | 1995-04-04 | Board Of Trustees Of The Leland Stanford Junior University Stanford University | Method to control leukocyte extravasation |
DE3852236T2 (de) | 1987-08-11 | 1995-04-06 | Univ Leland Stanford Junior | Verfahren zur Kontrolle der Leukozyten-Extravasation. |
US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
US5223392A (en) | 1988-01-25 | 1993-06-29 | Exocell, Inc. | Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore |
JP3095168B2 (ja) | 1988-02-05 | 2000-10-03 | エル. モリソン,シェリー | ドメイン‐変性不変部を有する抗体 |
WO1990007321A2 (en) | 1988-12-23 | 1990-07-12 | The Board Of Trustees Of The Leland Stanford Junior University | Lymphocyte receptor homing sequences and their uses |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5730978A (en) | 1989-09-01 | 1998-03-24 | Fred Hutchinson Cancer Research Center | Inhibition of lymphocyte adherence with α4β1-specific antibodies |
IL95501A (en) | 1989-09-01 | 1997-04-15 | Hutchinson Fred Cancer Res | Inhibition by antibodies of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction, and pharmaceutical compositions containing said antibodies |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
DK0531472T3 (da) | 1991-03-06 | 2003-12-01 | Merck Patent Gmbh | Humaniserede monoklonale antistoffer |
US5665595A (en) | 1991-06-07 | 1997-09-09 | Dowelanco | Immunoglobulins against insect tissue |
EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
ES2165851T3 (es) | 1991-11-25 | 2002-04-01 | Enzon Inc | Proteinas multivalentes que se unen a antigenos. |
US5871734A (en) | 1992-01-13 | 1999-02-16 | Biogen, Inc. | Treatment for asthma with VLA-4 blocking agents |
DE69309906T2 (de) | 1992-02-12 | 1997-11-06 | Biogen, Inc., Cambridge, Mass. | Behandlung für entzündungserkrankung des darmes |
US5932214A (en) | 1994-08-11 | 1999-08-03 | Biogen, Inc. | Treatment for inflammatory bowel disease with VLA-4 blockers |
AU4390893A (en) | 1992-05-21 | 1993-12-13 | Center For Blood Research, Inc., The | A novel receptor for alpha4 integrins and methods based thereon |
AU5732694A (en) | 1992-12-01 | 1994-06-22 | Protein Design Labs, Inc. | Humanized antibodies reactive with cd18 |
WO1994013312A1 (en) | 1992-12-15 | 1994-06-23 | The Board Of Trustees Of The Leland Stanford Junior University | Mucosal vascular addressin, dna and expression |
AU688751B2 (en) | 1993-01-12 | 1998-03-19 | Biogen Idec Ma Inc. | Recombinant anti-VLA4 antibody molecules |
WO1994017828A2 (en) | 1993-02-09 | 1994-08-18 | Biogen, Inc. | Treatment for insulin dependent diabetes |
US6017695A (en) | 1993-03-26 | 2000-01-25 | Becton Dickinson And Company | Nucleic acids encoding human cell adhesion molecule |
JPH06303990A (ja) | 1993-04-24 | 1994-11-01 | Kanebo Ltd | モノクローナル抗体、それを産生するハイブリドーマおよび該抗体の製造方法 |
WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
ES2424292T3 (es) | 1994-01-25 | 2013-09-30 | Biogen Idec Ma Inc. | Anticuerpos humanizados contra la molécula de adhesión leucocitaria VLA-4 |
US5594120A (en) | 1994-02-18 | 1997-01-14 | Brigham And Women's Hospital, Inc. | Integrin alpha subunit |
US5610281A (en) | 1994-05-03 | 1997-03-11 | Brigham & Women's Hospital, Inc. | Antibodies for modulating heterotypic E-cadherin interactions with human T lymphocytes |
GB2292079B (en) | 1994-08-12 | 1998-07-15 | Flexpharm Ltd | Coated prednisolone preparation for the treatment of inflamatory bowel disease |
US5624321A (en) | 1994-12-23 | 1997-04-29 | Snyder; Stephen D. | Spring-actuated swing device |
MX9706049A (es) | 1995-02-10 | 1998-02-28 | Leukosite Inc | Adresinas vasculares mucosas y sus usos. |
US7750137B2 (en) | 1995-09-01 | 2010-07-06 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressins |
US6551593B1 (en) | 1995-02-10 | 2003-04-22 | Millennium Pharmaceuticals, Inc. | Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam |
US7803904B2 (en) | 1995-09-01 | 2010-09-28 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressing and uses thereof |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US6037324A (en) | 1996-01-04 | 2000-03-14 | Leukosite, Inc. | Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor |
US6015662A (en) | 1996-01-23 | 2000-01-18 | Abbott Laboratories | Reagents for use as calibrators and controls |
US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
GB0007911D0 (en) * | 2000-03-30 | 2000-05-17 | Novartis Ag | Organic compounds |
US20010046496A1 (en) * | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
CA2868614A1 (en) * | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
US7053202B2 (en) | 2001-10-19 | 2006-05-30 | Millennium Pharmaceuticals, Inc. | Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor |
PT2336184E (pt) | 2002-02-25 | 2015-03-09 | Biogen Idec Inc | Administração de agentes para o tratamento da inflamação |
CA2485681C (en) | 2002-05-24 | 2012-10-16 | Millennium Pharmaceuticals, Inc. | Ccr9 inhibitors and methods of use thereof |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
EP2256116A3 (en) | 2002-11-18 | 2011-11-16 | ChemoCentryx, Inc. | Aryl sulfonamides |
US20040191243A1 (en) | 2002-12-13 | 2004-09-30 | Bei Chen | System and method for stabilizing antibodies with histidine |
WO2004075913A1 (ja) | 2003-02-28 | 2004-09-10 | Chugai Seiyaku Kabushiki Kaisha | タンパク質含有安定化製剤 |
ATE480567T1 (de) | 2003-04-04 | 2010-09-15 | Genentech Inc | Hochkonzentrierter antikörper und proteinformulierungen |
BRPI0515602B1 (pt) | 2004-09-03 | 2021-08-17 | Genentech, Inc | Anticorpo anti-beta7 humanizado, método de inibição da interação de subunidade de integrina beta7 humana, composição e uso de um anticorpo |
GT200600031A (es) * | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
US20080248047A1 (en) * | 2005-03-08 | 2008-10-09 | Tapan Das | Platform Antibody Compositions |
WO2007007159A2 (en) | 2005-07-11 | 2007-01-18 | Pfizer Limited | Anti-madcam antibodies to treat uterine disorders |
EP1948691A1 (en) | 2005-11-17 | 2008-07-30 | Millennium Pharmaceuticals, Inc. | HUMANIZED IMMUNOGLOBULIN REACTIVE WITH a4ß7INTEGRIN |
CA2638811A1 (en) | 2006-02-03 | 2007-08-16 | Medimmune, Llc | Protein formulations |
CN101426527A (zh) * | 2006-02-03 | 2009-05-06 | 米迪缪尼有限公司 | 蛋白质制剂 |
TW200806317A (en) * | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
SMP200800064B (it) | 2006-04-21 | 2009-11-06 | Novartis Ag | Composizioni farmaceutiche di anticorpi anti-cd40 antagonista |
WO2008071394A1 (en) * | 2006-12-11 | 2008-06-19 | F. Hoffmann-La Roche Ag | Abeta antibody parenteral formulation |
US9193790B2 (en) | 2006-12-07 | 2015-11-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of antagonists of the interaction between HIV GP120 and A4B7 integrin |
UA107557C2 (xx) * | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
US9111016B2 (en) | 2007-07-06 | 2015-08-18 | Stereotaxis, Inc. | Management of live remote medical display |
SG185286A1 (en) * | 2007-12-13 | 2012-11-29 | Glaxo Group Ltd | Compositions for pulmonary delivery |
IL188647A0 (en) * | 2008-01-08 | 2008-11-03 | Orina Gribova | Adaptable structured drug and supplements administration system (for oral and/or transdermal applications) |
KR20100138908A (ko) * | 2008-02-07 | 2010-12-31 | 암젠 인코퍼레이티드 | 안정화된 단백질 조성물 |
WO2009141239A1 (en) | 2008-05-20 | 2009-11-26 | F. Hoffmann-La Roche Ag | A pharmaceutical formulation comprising an antibody against ox40l, uses thereof |
ES2751946T3 (es) | 2009-03-20 | 2020-04-02 | Amgen Inc | Anticuerpo antagonista específico del heterodímero alfa-4-beta-7 |
CN101533504A (zh) * | 2009-04-27 | 2009-09-16 | 刘文祥 | 电子医务系统及其装置 |
RU2012139181A (ru) | 2010-02-26 | 2014-04-10 | Ново Нордиск А/С | Стабильная композиция, содержащая антитело |
UA116189C2 (uk) * | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
TWI832619B (zh) * | 2011-05-02 | 2024-02-11 | 美商千禧製藥公司 | 抗-α4β7抗體之調配物 |
-
2012
- 2012-05-02 TW TW111148303A patent/TWI832619B/zh active
- 2012-05-02 SI SI201231076T patent/SI2704742T1/sl unknown
- 2012-05-02 KR KR1020187018702A patent/KR102014512B1/ko active IP Right Grant
- 2012-05-02 CN CN201280021789.8A patent/CN103533959B/zh active Active
- 2012-05-02 UY UY0001034054A patent/UY34054A/es not_active Application Discontinuation
- 2012-05-02 MY MYPI2013003974A patent/MY188820A/en unknown
- 2012-05-02 DK DK12722973.0T patent/DK2704742T3/en active
- 2012-05-02 CA CA3051418A patent/CA3051418C/en active Active
- 2012-05-02 WO PCT/US2012/036069 patent/WO2012151247A2/en active Application Filing
- 2012-05-02 RS RS20171015A patent/RS56429B1/sr unknown
- 2012-05-02 KR KR1020197024347A patent/KR102136208B1/ko active IP Right Grant
- 2012-05-02 EA EA201391613A patent/EA032625B1/ru not_active IP Right Cessation
- 2012-05-02 TW TW106123969A patent/TWI698254B/zh active
- 2012-05-02 EP EP24167554.5A patent/EP4403579A3/en active Pending
- 2012-05-02 AR ARP120101540A patent/AR086238A1/es not_active Application Discontinuation
- 2012-05-02 TW TW108104506A patent/TWI723339B/zh active
- 2012-05-02 HU HUE12722973A patent/HUE036664T2/hu unknown
- 2012-05-02 LT LTEP12722973.0T patent/LT2704742T/lt unknown
- 2012-05-02 KR KR1020237002891A patent/KR20230021758A/ko not_active Application Discontinuation
- 2012-05-02 TW TW109140548A patent/TWI799757B/zh active
- 2012-05-02 CN CN201810453956.5A patent/CN108969761A/zh active Pending
- 2012-05-02 IL IL305583A patent/IL305583A/en unknown
- 2012-05-02 PL PL12722973T patent/PL2704742T3/pl unknown
- 2012-05-02 PT PT127229730T patent/PT2704742T/pt unknown
- 2012-05-02 EP EP24167547.9A patent/EP4378959A3/en active Pending
- 2012-05-02 EP EP17180247.3A patent/EP3311834A1/en active Pending
- 2012-05-02 TW TW101115710A patent/TWI638661B/zh active
- 2012-05-02 EP EP12722973.0A patent/EP2704742B1/en not_active Revoked
- 2012-05-02 ES ES12722973.0T patent/ES2646717T3/es active Active
- 2012-05-02 SG SG2013080940A patent/SG194730A1/en unknown
- 2012-05-02 ME MEP-2017-227A patent/ME02858B/me unknown
- 2012-05-02 KR KR1020217031194A patent/KR102493433B1/ko active IP Right Review Request
- 2012-05-02 CA CA2834900A patent/CA2834900C/en active Active
- 2012-05-02 KR KR1020207020503A patent/KR102308938B1/ko active IP Right Grant
- 2012-05-02 US US14/114,835 patent/US10040855B2/en active Active
- 2012-05-02 EP EP24167555.2A patent/EP4438625A2/en active Pending
- 2012-05-02 MX MX2017007134A patent/MX367097B/es unknown
- 2012-05-02 KR KR1020137031205A patent/KR101875155B1/ko active IP Right Grant
- 2012-05-02 MX MX2013012725A patent/MX354101B/es active IP Right Grant
- 2012-05-02 CN CN201810453958.4A patent/CN108969469A/zh active Pending
- 2012-05-02 JP JP2014509377A patent/JP6190359B2/ja active Active
- 2012-05-02 KR KR1020177012979A patent/KR101884406B1/ko active IP Right Grant
- 2012-05-02 AU AU2012250872A patent/AU2012250872B2/en active Active
- 2012-05-02 GE GEAP201213302A patent/GEP20186866B/en unknown
- 2012-05-02 PE PE2013002433A patent/PE20141672A1/es active IP Right Grant
- 2012-05-02 CN CN201711133991.0A patent/CN107998388B/zh active Active
-
2013
- 2013-10-29 DO DO2013000252A patent/DOP2013000252A/es unknown
- 2013-10-29 CR CR20130556A patent/CR20130556A/es unknown
- 2013-10-30 CL CL2013003145A patent/CL2013003145A1/es unknown
- 2013-10-31 MX MX2019009244A patent/MX2019009244A/es unknown
- 2013-10-31 MX MX2021008112A patent/MX2021008112A/es unknown
- 2013-10-31 ZA ZA2013/08168A patent/ZA201308168B/en unknown
- 2013-10-31 IL IL229169A patent/IL229169B/en active IP Right Grant
- 2013-11-01 CO CO13259852A patent/CO6801648A2/es unknown
-
2017
- 2017-04-05 CL CL2017000829A patent/CL2017000829A1/es unknown
- 2017-05-10 JP JP2017094129A patent/JP6467457B2/ja active Active
- 2017-06-21 AU AU2017204192A patent/AU2017204192B2/en active Active
- 2017-09-28 HR HRP20171457TT patent/HRP20171457T1/hr unknown
- 2017-10-11 CY CY20171101057T patent/CY1119436T1/el unknown
- 2017-10-27 ZA ZA2017/07310A patent/ZA201707310B/en unknown
-
2018
- 2018-05-18 US US15/983,791 patent/US20180327497A1/en not_active Abandoned
- 2018-06-15 US US16/009,865 patent/US20180346578A1/en not_active Abandoned
- 2018-10-12 HK HK18113059.1A patent/HK1253911A1/zh unknown
- 2018-10-17 PH PH12018502221A patent/PH12018502221A1/en unknown
-
2019
- 2019-01-11 JP JP2019003265A patent/JP6751450B2/ja active Active
- 2019-07-17 PH PH12019501662A patent/PH12019501662A1/en unknown
- 2019-08-15 AU AU2019216679A patent/AU2019216679B2/en active Active
-
2020
- 2020-01-26 IL IL272237A patent/IL272237B/en unknown
- 2020-02-11 US US16/787,521 patent/US11560434B2/en active Active
- 2020-05-21 IL IL274846A patent/IL274846A/en unknown
- 2020-06-12 CL CL2020001579A patent/CL2020001579A1/es unknown
- 2020-08-14 JP JP2020136927A patent/JP7107997B2/ja active Active
-
2021
- 2021-04-23 US US17/239,512 patent/US20210340261A1/en active Pending
- 2021-08-31 AU AU2021225160A patent/AU2021225160B2/en active Active
-
2022
- 2022-02-23 IL IL290848A patent/IL290848A/en unknown
- 2022-02-23 IL IL290849A patent/IL290849A/en unknown
- 2022-06-10 EC ECSENADI202246340A patent/ECSP22046340A/es unknown
- 2022-07-14 JP JP2022112814A patent/JP2022132430A/ja active Pending
- 2022-10-13 US US18/046,450 patent/US20230312727A1/en active Pending
-
2023
- 2023-12-04 AU AU2023274233A patent/AU2023274233A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL290848A (en) | Formulation for anti-antibody alpha 4 in cell 7 | |
IL275038A (en) | Formulation for anti-antibody alpha 4 in cell 7 | |
IL276234B (en) | Antibody compositions | |
HRP20180640T1 (hr) | Anti-b7-h3 antitijelo | |
IL259826A (en) | Anti-alphabetatisiar antibody | |
EP2694539A4 (en) | POLYCLONAL ANTIBODY COMPOSITIONS | |
EP2769988A4 (en) | ANTI-GAP43 ANTIBODY |